New combo therapy aims to tame transplant complication
NCT ID NCT07576010
First seen May 09, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-phase study tests whether a low dose of steroids combined with the drug ruxolitinib can safely control grade II acute graft-versus-host disease (aGVHD) after a stem cell transplant. The trial involves 30 people with blood cancers who have received a donor stem cell transplant. The goal is to see if this combination can prevent the disease from getting worse or becoming chronic, while reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-GRAFT-VERSUS-HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.